Clinical Evaluation of Two Silicone Hydrogel Daily Disposable Contact Lenses
1 other identifier
interventional
286
1 country
13
Brief Summary
The purpose of this investigation is to evaluate the short-term, clinical performance of two silicone hydrogel daily disposable contact lenses.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2015
Shorter than P25 for not_applicable
13 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2015
CompletedFirst Submitted
Initial submission to the registry
November 2, 2015
CompletedFirst Posted
Study publicly available on registry
November 3, 2015
CompletedResults Posted
Study results publicly available
July 20, 2016
CompletedJuly 5, 2017
June 1, 2017
2 months
November 2, 2015
June 10, 2016
June 13, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Overall Comfort
Overall comfort was assessed using the Contact Lens User Experienceâ„¢ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. Please note this was a 2 treatment by 3 period study design. Therefore, some subjects were randomized to receive one of the study lenses twice, hence the number of observations were summarized per lens type. For the senofilcon A lens 134+138+134=406 (Observations- 1 per subject per period, however 1 observation was not recorded) from period 1, 2 and 3 respectively. For the delefilcon A lens 138+134+138=410 from period 1, 2 and 3 respectively.
1 Week
Study Arms (2)
Sequence 1: Test Control Test
ACTIVE COMPARATORTest/control/test using the Johnson \& Johnson Vision Care (JJVC) Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each in between lenses for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
Sequence 2: Control Test Control
ACTIVE COMPARATORControl/test/control using the JJVC Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
Interventions
Eligibility Criteria
You may qualify if:
- The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
- The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
- The subject must be between (and including) 18 and 39 years of age.
- The subject must be an adapted wearer of spherical soft contact lenses in both eyes. That is, the subject must wear their habitual lenses at least five (5) days per week and eight (8) hours per day worn for at least 30 days immediately preceding the study.
- The subject must have vertex-corrected distance refraction that allows a plano over-refraction with the available contact lens powers of -0.50 to -6.00 Diopters (D) in each eye.
- The subject must have refractive astigmatism, if present, of less than or equal to 1.00 D in each eye.
- The subject must have best corrected visual acuity of 20/25 or better in each eye.
You may not qualify if:
- Currently pregnant or breastfeeding (subjects who become pregnant during the study will be discontinued).
- Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
- Any autoimmune disease or use of medication, which may interfere with contact lens wear.
- Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, or aphakia.
- Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK), etc.).
- Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
- Any ocular infection.
- Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
- Monovision, multi-focal, toric, or extended wear contact lens correction.
- Participation in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
- History of binocular vision abnormality or strabismus that is likely to affect successful contact lens wear.
- Any infectious disease (e.g., hepatitis, tuberculosis) or contagious immunosuppressive diseases (e.g., HIV) by self-report.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (13)
Becky Bizzle, OD
Montgomery, Alabama, 36117, United States
Complete Family Eye Care of Fruit Cove
Fruit Cove, Florida, 32259, United States
Golden Family Eyecare
Sarasota, Florida, 34232, United States
St. Lucy's Vision Center
Tampa, Florida, 33625, United States
Eye Associates of Winter Park
Winter Park, Florida, 32792, United States
VisualEyes, Inc.
Roswell, Georgia, 30076, United States
Advantage Eyecare Associates, LLC
Neodesha, Kansas, 66757, United States
Sacco Eye Group
Vestal, New York, 13850, United States
Advanced Family Eye Care
Denver, North Carolina, 28037, United States
total Eye Care PA
Memphis, Tennessee, 38119, United States
Brian Frazier, OD
Jacksonville, Texas, 17576, United States
Timothy R. Poling, OD
Roanoke, Virginia, 24153, United States
Ziegler Leffingwell Eyecare
West Allis, Wisconsin, 53227, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Brian Pall, O.D., M.S., F.A.A.O - Senrior Principal Research Optometrist
- Organization
- Johnson & Johnson Vision Care Inc.
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- GT60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 2, 2015
First Posted
November 3, 2015
Study Start
September 1, 2015
Primary Completion
November 1, 2015
Study Completion
November 1, 2015
Last Updated
July 5, 2017
Results First Posted
July 20, 2016
Record last verified: 2017-06